Elliot Tapper
@ebtapper
Followers
42K
Following
32K
Media
3K
Statuses
15K
Hepatologist @michiganliver @vaannarbor; #cirrhosis; encephalopathy; frailty; quality improvement; father; husband. #livertwitter Co-EIC of @HepCommJournal
Ann Arbor, MI
Joined September 2011
Join the community here:
roon.com
Where the world’s best physicians share knowledge and advance medicine—together.
0
0
0
Want to be more? The journey begins in the mind. Capable. Confident. Anytime, anywhere.
19
44
335
You are the best advocate for hepatitis b care
Great summary of the disastrous #ACIP meeting. And tx for quoting my testimony. “We cannot predict a child's future risk,” Wang told the committee. “Like seat belts, our overall risk of getting into an accident are low, but we universally wear them because we cannot control the
0
1
7
1/ With the passing of Dr. Ethan Neumann at age 27 from #fibrolamellar carcinoma, I want to raise awareness of this devastating disease and share answers to several questions I’ve received ▶️About Ethan: https://t.co/qKvfxi2XdJ
3
15
87
Yes! It is great and It’s coming! Stay tuned @AmerGastroAssn @AASLDtweets
The @AmerGastroAssn @AASLDtweets academic skills workshop was so helpful to me in understanding how to build a career in academics. Has the information for 2026 been released? I can't seem to find it, and have some fellows who will greatly benefit!
3
0
13
Please join in the conversation about our recent clinical trial. I’d be happy to hear your thoughts on precision nutrition in MASLD
A randomized trial of the Mediterranean versus low fat diet in @HepCommJournal Both are good! https://t.co/nY2Lq7tCHS Recommending the Med diet to all patients with fat in their liver is, let’s be honest, goofy. Let’s focus on what matters and what is feasible
0
2
7
One of the interesting things about this paper is that they obtained PNPLA3 genotypes in everyone and guess what it didn’t matter! https://t.co/nY2Lq7tCHS I recently heard that some people are spending $$$ to check their patients genotype… thoughts?
journals.lww.com
hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m2 were randomized to a 12-week moderately hypocaloric MD or LFD...
2
1
10
One of the interesting things about this paper is that they obtained PNPLA3 genotypes in everyone and guess what it didn’t matter! https://t.co/nY2Lq7tCHS I recently heard that some people are spending $$$ to check their patients genotype… thoughts?
journals.lww.com
hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m2 were randomized to a 12-week moderately hypocaloric MD or LFD...
A randomized trial of the Mediterranean versus low fat diet in @HepCommJournal Both are good! https://t.co/nY2Lq7tCHS Recommending the Med diet to all patients with fat in their liver is, let’s be honest, goofy. Let’s focus on what matters and what is feasible
1
2
17
A randomized trial of the Mediterranean versus low fat diet in @HepCommJournal Both are good! https://t.co/nY2Lq7tCHS Recommending the Med diet to all patients with fat in their liver is, let’s be honest, goofy. Let’s focus on what matters and what is feasible
journals.lww.com
hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m2 were randomized to a 12-week moderately hypocaloric MD or LFD...
4
8
42
@ebtapper Thank you @ebtapper for supporting @BavenoCoop ! The rule of five was first proposed by Monica Pons, @JuanAbraldes and Joan Genesca in this very nice paper, in which I collaborated https://t.co/3OREDUGhBo Looking forward to Baveno VIII!
journals.lww.com
ude clinically significant portal hypertension (CSPH) in clinical practice. METHODS: This is an international cohort study including patients with paired LSM/hepatic venous pressure gradient (HVPG),...
0
3
16
The rule of 5 is one of the most important contributions to clinical hepatology It brought clarity to chaos As I understand, it was first conceived by @docberza.
🚨 Updated @BavenoCoop "Rule-of-5" Figure by the #ANTICIPATE ±NASH team 📕in @JHepatology 🔗 https://t.co/yy92JSulCj
3
23
105
A meta-analysis shows that in liver disease due to alcohol use, psychosocial therapy reduces return-to-drinking by ~50%: 👉 Treating AUD in CLD is NOT just about prescribing pills. 👉 Psychosocial therapy + pharmacotherapy = best outcomes. Offer both ! https://t.co/Enl66kRowV
2
33
60
🧠 Why Series Why does early paracentesis on admission matter in cirrhosis with ascites? 💉⏱️ 🌟Because delaying the tap delays diagnosis & increases mortality. From infection detection → safer management → better outcomes, @AbigailTamiMD breaks it down brilliantly.
1
10
16
✨Don’t miss the LAST ACCREDITED SCOPE Rounds Gastroenterology 2025 Session on “The Top Three Things You Might Not Be Doing for Your Patients With Cirrhosis” with Dr. Elliot Tapper! 🗓️Tuesday, December 2 at 7:00 PM ET 👉Register now: https://t.co/CStCDcT0aU
0
6
8
📑 Hepatobiliary complications in patients with #SickleCellDisease: A 30-year review of 1009 patients‼️ #LiverX #OpenAccess
https://t.co/2RbLg5GdD4
0
13
43
📑 Awareness of #MASLD in 4 major cities in the United States 🇺🇸 is LOW‼️ https://t.co/Oycis0bEuq
1
14
22
THIS
I used to think alcohol counseling was black-and-white: full abstinence or nothing. But many patients who just cut down improve fibrosis and even recompensate. So lately I sit with those who can't quit fully and negotiate achievable reductions. It's surprising how much it helps.
0
8
36
I will be there
1
7
47
🧠 Why Series Why does cirrhosis throw off hemodynamics and cardiac function? 🫀🤯 From portal hypertension → vasodilation → hyperdynamic circulation → cirrhotic cardiomyopathy, this article by Hampton Sasser, MD breaks it down beautifully. @ebtapper Chip Bowman, MD
1
12
34
Eplerenone is both weaker and shorter-acting than spironolactone It is perfectly reasonable and in fact appropriate to give some patients 200-300mg twice daily - if that is what is required to avoid volume overload
0
1
15